Completed × Carcinoma, Transitional Cell × Gastrointestinal × Clear all Phase 1a/1b Study of TPST-1495 as a Single Agent and in Combination With Pembrolizumab in Subjects With Solid Tumors
Phase 1 Completed
89 enrolled
Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies
Phase 1/2 Completed
145 enrolled 47 charts
Phase 1, First-in-human, Dose-finding and Expansion Study to Evaluate XmAb®808 in Combination With Pembrolizumab in Advanced Solid Tumors
Phase 1 Completed
60 enrolled
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099280 in Participants With Advanced Solid Tumors
Phase 1 Completed
182 enrolled
Phase 1/2 Study of APR-246 in Combination With Pembrolizumab in Subjects With Solid Tumor Malignancies
Phase 1/2 Completed
40 enrolled 11 charts
A Study of BMS-986416 With and Without Nivolumab in Select Solid Tumors
Phase 1 Completed
67 enrolled
Nivolumab (Opdivo®) Plus ABI-009 (Nab-rapamycin) for Advanced Sarcoma and Certain Cancers
Phase 1/2 Completed
34 enrolled 14 charts
LYT-200 Alone and in Combination With Chemotherapy or Tislelizumab in Patients With Locally Advanced or Metastatic Solid Tumors
Phase 1/2 Completed
44 enrolled
A Study of Ramucirumab Plus Pembrolizumab in Participants With Gastric or GEJ Adenocarcinoma, NSCLC, Transitional Cell Carcinoma of the Urothelium, or Biliary Tract Cancer
Phase 1 Completed
175 enrolled 23 charts
DUET-3
Phase 1 Completed
198 enrolled
A Safety and Tolerability Study of NC318 in Subjects With Advanced or Metastatic Solid Tumors
Phase 1/2 Completed
109 enrolled 25 charts
A Study of a Personalized Neoantigen Cancer Vaccine
Phase 1/2 Completed
29 enrolled
A Study to Evaluate ONM-100, an Intraoperative Fluorescence Imaging Agent for the Detection of Cancer
Phase 2 Completed
30 enrolled 20 charts
TPST-1120 as Monotherapy and in Combination With Nivolumab in Subjects With Advanced Cancers
Phase 1 Completed
38 enrolled
FT500 as Monotherapy and in Combination With Immune Checkpoint Inhibitors in Subjects With Advanced Solid Tumors
Phase 1 Completed
37 enrolled
DUET-4
Phase 1 Completed
78 enrolled
PIVOT-02
Phase 1/2 Completed
557 enrolled 22 charts
Arginase-1 Peptide Vaccine in Patients With Metastatic Solid Tumors
Phase 1 Completed
13 enrolled 10 charts
DUET-2
Phase 1 Completed
150 enrolled
A Phase 1 Study of Mixed Bacteria Vaccine (MBV) in Patients With Tumors Expressing NY-ESO-1 Antigen
Phase 1 Completed
17 enrolled 14 charts
A Study Exploring the Safety and Efficacy of INCAGN01949 in Combination With Immune Therapies in Advanced or Metastatic Malignancies
Phase 1/2 Completed
52 enrolled 25 charts
A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies
Phase 1 Completed
40 enrolled
A Safety and Tolerability Study of INCAGN02385 in Select Advanced Malignancies
Phase 1 Completed
22 enrolled
A Study of Personalized Neoantigen Cancer Vaccines
Completed
93 enrolled
A Phase 1 Study of CC-486 as a Single Agent and in Combination With Carboplatin or ABI-007 in Subjects With Relapsed or Refractory Solid Tumors
Phase 1 Completed
169 enrolled
Phase II Study of Brivanib (BMS-582664) to Treat Multiple Tumor Types
Phase 2 Completed
597 enrolled